Table 2.
Comparison of hematological variables between survivor and non-survivor groups.
| Survivor Covid-19 | Non-survivor Covid-19 | *p-value | ||
|---|---|---|---|---|
| Median (25 th quartile-75th quartile) | Median (25 th quartile-75th quartile) | |||
| Parameters | Reference range | |||
| BASO (pre) 109/L | 0.01–0.07 | 0.02 (0.01–0.04) | 0.02 (0.01–0.04) | 0.869 |
| BASO (post) 109/L | 0.03 (0.02–0.05) | 0.02 (0.01–0.05) | 0.262 | |
| ESO (pre) 109/L | 0.01–0.4 | 0.04 (0.01–0.12) | 0.03 (0.00–0.12) | 0.232 |
| ESO (post) 109/L | 0.05 (0.00–0.15) | 0.01 (0.00–0.08) | 0.000 | |
| HCT (pre) % | 36–48 | 39.55 (36.00–43.20) | 38.80 (34.90–42.30) | 0.041 |
| HCT (post) % | 37.10 (33.60–40.70) | 35.60 (31.20–39.90) | 0.022 | |
| HGB(pre) g/L | 13.5–17.5 | 13.30 (12.00–14.65) | 13.10 (11.50–14.50) | 0.016 |
| HGB (post) g/L | 12.50 (11.10–13.80) | 11.75 (9.90–13.30) | 0.002 | |
| LYM (pre) 109/L | 1–5 | 1.46 (0.99–2.03) | 1.32 (0.85–1.88) | 0.015 |
| LYM (post) 109/L | 1.24 (0.83–1.89) | 0.74 (0.42–1.23) | 0.000 | |
| MCH (pre) pg | 26–34 | 28.60 (27.30–29.60) | 28.80 (27.20–30.10) | 0.041 |
| MCH (post) pg | 28.60 (27.20–29.50) | 28.50 (26.90–29.70) | 0.989 | |
| MCHC (pre) g/dL | 33.80 (32.90–34.70) | 33.50 (32.40–34.60) | 0.004 | |
| MCHC (post) g/dL | 33.70 (32.60 – 34.40) | 33.20 (32.00–34.10) | 0.004 | |
| MCV (pre) fL | 80–96 | 83.90 (80.80–87.00) | 85.20 (81.80–88.90) | 0.000 |
| MCV (post) fL | 84.40 (81.20–87.30) | 85.55 (81.55–89.25) | 0.045 | |
| MONO (pre) 109/L | 0.1–1 | 0.51 (0.38–0.67) | 0.56 (0.44–0.72) | 0.000 |
| MONO (post) 109/L | 0.51 (0.37–0.68) | 0.42 (0.27–0.64) | 0.000 | |
| MPV (pre) fL | 9.1–11.9 | 10.30 (9.70–10.90) | 10.30 (9.55–11.00) | 0.613 |
| MPV (post) fL | 10.40 (9.90–11.00) | 11.00 (10.20–11.70) | 0.000 | |
| NEU (pre) 109/L | 1.8–6.98 | 4.05 (2.85–5.85) | 5.25 (3.98–7.65) | 0.000 |
| NEU (post) 109/L | 5.11 (3.53–7.99) | 8.59 (5.01–13.21) | 0.000 | |
| PLT (pre) 109/L | 150–450 | 229.00 (184.00–287.00) | 192.50 (138.00–204.00) | 0.000 |
| PLT (post) 109/L | 243.00 (182.00–311.00) | 197.50 (149.00–213.50) | 0.000 | |
| RBC (pre) 1012/L | 4.5–6 | 4.74 (4.36–5.14) | 3.21 (3.16–3.98) | 0.000 |
| RBC (post) 1012/L | 4.41 (3.99–4.84) | 3.19 (2.55–3.78) | 0.007 | |
| RDW (pre) % | 11–14 | 13.10 (12.50–13.90) | 14.00 (13.20–15.40) | 0.000 |
| RDW (post) % | 13.60 (12.80–14.70) | 14.95 (13.75–16.80) | 0.000 | |
| WBC(pre) 109/L | Male: 3.91–10.9Female: 4.49–12.68 | 6.5 (5.00–8.30) | 7.80 (6.20–10.10) | 0.000 |
| WBC (post) 109/L | 7.30 (5.60–10.10) | 10.15 (6.75–14.80) | 0.000 |
BASO: Basophil count; ESO: Eosinophil count; HCT: Hematocrit; HGB: Hemoglobin; LYM: Lymphocyte count; MCH: Mean corpuscular hemoglobin; MCHC: Mean erythrocyte hemoglobın concentratıon; MCV: Mean corpuscular volume; MONO: Monocyte count; MPV: Mean platelet volume; NEU: Neutrophil count; PLT: Platelet count; RBC: Red blood cells; RDW: Red cell distribution width; WBC: White blood cell count; IQR: interquartile range; The p values indicate the comparison of the survivor and non-survivor groups in pre-post measurements and they are bold when p < 0.05.